Page last updated: 2024-11-05

ticlopidine and Nervous System Disorders

ticlopidine has been researched along with Nervous System Disorders in 9 studies

Ticlopidine: An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.
ticlopidine : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group.

Research Excerpts

ExcerptRelevanceReference
"To evaluate the effects of treatments with clopidogrel plus aspirin (dual therapy) on early neurological deterioration (END) and outcomes at 6 months in patients with acute large artery atherosclerosis (LAA) stroke."9.20Clopidogrel plus aspirin prevents early neurologic deterioration and improves 6-month outcome in patients with acute large artery atherosclerosis stroke. ( Chi, L; Liao, D; Lin, J; Wang, C; Yi, X; Zhang, B, 2015)
" The prevalence of adverse events was assessed at each visit through a direct interview."6.78Comparison of antiplatelet effect and safety of clopidogrel napadisilate with clopidogrel bisulfate in coronary artery disease patients: multi-center, randomized, double-blind, phase IV, non-inferiority clinical trial. ( Choi, DJ; Kang, HJ; Kim, HS; Kim, MA; Koo, BK; Lee, HY; Lee, S; Oh, BH; Park, KW, 2013)
"To evaluate the effects of treatments with clopidogrel plus aspirin (dual therapy) on early neurological deterioration (END) and outcomes at 6 months in patients with acute large artery atherosclerosis (LAA) stroke."5.20Clopidogrel plus aspirin prevents early neurologic deterioration and improves 6-month outcome in patients with acute large artery atherosclerosis stroke. ( Chi, L; Liao, D; Lin, J; Wang, C; Yi, X; Zhang, B, 2015)
" Oral administration of ticlopidine inhibited the transient thrombocytopenia caused by ADP."3.66Inhibition of thrombocytopenic episodes caused by the Arthus reaction, the sub-lethal Forssman reaction and ADP. ( Butler, KD; White, AM, 1980)
"Thrombotic thrombocytopenic purpura is a thrombotic microangiopathy related to a severe deficiency of ADAMTS13 (a disintegrin and metalloprotease with thrombospondin type 1 repeats, member 13; activity <10%)."2.82Epidemiology and pathophysiology of adulthood-onset thrombotic microangiopathy with severe ADAMTS13 deficiency (thrombotic thrombocytopenic purpura): a cross-sectional analysis of the French national registry for thrombotic microangiopathy. ( Azoulay, E; Benhamou, Y; Boisseau, P; Coppo, P; de Maistre, E; Delmas, Y; Galicier, L; Mariotte, E; Perez, P; Poullin, P; Provôt, F; Rondeau, E; Stepanian, A; Veyradier, A; Zouiti, F, 2016)
" The prevalence of adverse events was assessed at each visit through a direct interview."2.78Comparison of antiplatelet effect and safety of clopidogrel napadisilate with clopidogrel bisulfate in coronary artery disease patients: multi-center, randomized, double-blind, phase IV, non-inferiority clinical trial. ( Choi, DJ; Kang, HJ; Kim, HS; Kim, MA; Koo, BK; Lee, HY; Lee, S; Oh, BH; Park, KW, 2013)

Research

Studies (9)

TimeframeStudies, this research(%)All Research%
pre-19901 (11.11)18.7374
1990's0 (0.00)18.2507
2000's2 (22.22)29.6817
2010's6 (66.67)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Lee, S1
Lee, HY1
Park, KW1
Kang, HJ1
Koo, BK1
Kim, HS1
Choi, DJ1
Kim, MA1
Oh, BH1
Fornós-Garrigós, A1
Orozco-Beltrán, D1
Gil-Guillén, VF1
Puig-Barberà, J1
Fluixa, C1
Fernández, A1
Wang, C2
Yi, X2
Zhang, B1
Liao, D1
Lin, J2
Chi, L1
Mariotte, E1
Azoulay, E1
Galicier, L1
Rondeau, E1
Zouiti, F1
Boisseau, P1
Poullin, P1
de Maistre, E1
Provôt, F1
Delmas, Y1
Perez, P1
Benhamou, Y1
Stepanian, A1
Coppo, P1
Veyradier, A1
Liu, P1
Fu, C1
Chen, Y1
Fiorella, D1
Litz, RJ1
Gottschlich, B1
Stehr, SN1
Butler, KD1
White, AM1
Zauner, C1
Funk, GC1
Birnbacher, R1

Clinical Trials (3)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Comparison of Antiplatelet Effect and Safety of Clopidogrel Napadisilate With Clopidogrel Bisulfate in Coronary Artery Disease Patients: Multi-center, Randomized, Double-blind, Phase IV Clinical Trial[NCT01830491]Phase 4162 participants (Actual)Interventional2009-03-31Completed
Early Intensive Medical Therapy for the Prevention of Early Neurological Deterioration in Branch Atheromatous Disease[NCT04824911]Phase 2424 participants (Anticipated)Interventional2021-03-23Recruiting
ADAMTS13-related Prognostic Factors in Adult and Pediatric Thrombotic Thrombocytopenic Purpura[NCT00426686]153 participants (Actual)Observational2006-11-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

1 review available for ticlopidine and Nervous System Disorders

ArticleYear
Anti-thrombotic medications for the neurointerventionist: aspirin and clopidogrel.
    Journal of neurointerventional surgery, 2010, Volume: 2, Issue:1

    Topics: Aspirin; Clopidogrel; Fibrinolytic Agents; Humans; Nervous System Diseases; Neuroprotective Agents;

2010

Trials

3 trials available for ticlopidine and Nervous System Disorders

ArticleYear
Comparison of antiplatelet effect and safety of clopidogrel napadisilate with clopidogrel bisulfate in coronary artery disease patients: multi-center, randomized, double-blind, phase IV, non-inferiority clinical trial.
    American journal of cardiovascular drugs : drugs, devices, and other interventions, 2013, Volume: 13, Issue:6

    Topics: Aged; Clopidogrel; Coronary Artery Disease; Double-Blind Method; Drug Therapy, Combination; Female;

2013
Clopidogrel plus aspirin prevents early neurologic deterioration and improves 6-month outcome in patients with acute large artery atherosclerosis stroke.
    Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, 2015, Volume: 21, Issue:5

    Topics: Acute Disease; Aged; Aspirin; Atherosclerosis; Clopidogrel; Female; Humans; Male; Nervous System Dis

2015
Epidemiology and pathophysiology of adulthood-onset thrombotic microangiopathy with severe ADAMTS13 deficiency (thrombotic thrombocytopenic purpura): a cross-sectional analysis of the French national registry for thrombotic microangiopathy.
    The Lancet. Haematology, 2016, Volume: 3, Issue:5

    Topics: ADAMTS13 Protein; Adult; Autoantibodies; Autoimmune Diseases; Clopidogrel; Cohort Studies; Cross-Sec

2016

Other Studies

5 other studies available for ticlopidine and Nervous System Disorders

ArticleYear
Appropriateness of clopidogrel use according to current recommendations.
    Family practice, 2014, Volume: 31, Issue:6

    Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Clinical Audit; Clopidogrel; Electronic Health Rec

2014
Antiplatelet drug resistance is associated with early neurological deterioration in acute minor ischemic stroke in the Chinese population.
    Journal of neurology, 2016, Volume: 263, Issue:8

    Topics: Aged; Aged, 80 and over; Asian People; Aspirin; Brain Ischemia; Clopidogrel; Female; Humans; Male; M

2016
Spinal epidural hematoma after spinal anesthesia in a patient treated with clopidogrel and enoxaparin.
    Anesthesiology, 2004, Volume: 101, Issue:6

    Topics: Aged; Aged, 80 and over; Anesthesia, Spinal; Clopidogrel; Enoxaparin; Female; Fibrinolytic Agents; H

2004
Inhibition of thrombocytopenic episodes caused by the Arthus reaction, the sub-lethal Forssman reaction and ADP.
    Artery, 1980, Volume: 8, Issue:5

    Topics: Adenosine Diphosphate; Animals; Antibodies; Arthus Reaction; Aspirin; Dipyridamole; Forssman Antigen

1980
Platelet aggregation inhibition with ticlopidine in the treatment of stroke.
    Intensive care medicine, 2001, Volume: 27, Issue:3

    Topics: Acute Disease; Critical Care; Drug Eruptions; Drug Monitoring; Gastrointestinal Diseases; Humans; Ki

2001